Previous studies showed that the m6A RNA methyltransferases METTL3 and METTL14 enhance the response of colorectal cancer to immunotherapy by regulating the tumor immune microenvironment and negatively correlate with the STAT1 signaling pathway; these factors are potential new targets for antitumor immunotherapy [39]. This evidence concerns the gene METTL14 and neoplasm.